Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Kidney Int. 2013 Oct 2;85(2):265–275. doi: 10.1038/ki.2013.381

Figure 2. Donor genetic modification to prevent kidney xenograft rejection.

Figure 2

The targets of genetic modification are shown as filled boxes. Abbreviations: CIITA-DN, dominant-negative class II transactivator; CRP, complement regulatory protein; GnT-III, N-acetylglucosaminyltransferase III; GTKO, GalT knockout; h: human; HO-1, hemoxygenase-1; HT, H-transferase; Neu5Gc-KO, N-glycolylneuraminic acid knockout; HLA, human leukocyte antigen; p: pig; shTNFR1, soluble human TNF receptor 1; Tg: transgenic; TFPI, tissue factor pathway inhibitor; TM, thrombomodulin; TRAIL, TNF-related human apoptosis-inducing ligand.